N/A
Manufactured by RB Health (US) LLC
8,751 FDA adverse event reports analyzed
Last updated: 2026-04-15
DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by RB Health (US) LLC. The most commonly reported adverse reactions for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN include DRUG INEFFECTIVE, OVERDOSE, DIZZINESS, DIARRHOEA, ACCIDENTAL OVERDOSE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN.
Out of 5,052 classified reports for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 8,751 FDA FAERS reports that mention DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, OVERDOSE, DIZZINESS, DIARRHOEA, ACCIDENTAL OVERDOSE, COUGH. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list RB Health (US) LLC in connection with DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN. Always verify the specific product and NDC with your pharmacist.